Skip to main content

Ex-U.S. biotech executive fined for lying to auditors, charges dropped against CFO: SEC

The former chief business officer of U.S. biotechnology company Osiris Therapeutics Inc has agreed to pay a $40,000 civil penalty for lying to auditors, the Securities and Exchange Commission said on Thursday.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.